|
|
Article: Trasylol(R) (aprotinin injection) Therapy During Coronary Artery Bypass Graft Surgery Associated with Reduced Risk of Stroke; Fewer Blood Transfusions May be Linked to Reduced Stroke Risk.
- Article from:
- PR Newswire
- Article date:
- September 7, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
WEST HAVEN, Conn., Sept. 7 /PRNewswire/ -- Trasylol(R) (aprotinin injection) therapy was associated with a 47 percent relative risk reduction for stroke in patients undergoing coronary artery bypass graft (CABG) surgery, according to a study published today in the Journal of Thoracic and Cardiovascular Surgery.(1) Trasylol is the only drug treatment approved by the U.S. Food and Drug Administration (FDA) to reduce bleeding and the need for blood transfusions during CABG surgery.
The systematic review with meta-analysis evaluating data from 35 CABG clinical studies determined that use of Trasylol resulted in a 39 percent reduction in the risk for receiving any ...